Ceftolozane/tazobactam: A novel antipseudomonal cephalosporin and β-lactamase-inhibitor combination

Infection and Drug Resistance

Volumn 6, Issue , 2013, Pages 215-223

  Hong, Mai Chi ^a   Hsu, Donald I ^a,b   Bounthavong, Mark ^c,d  

^a WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^b ST JOSEPH HOSPITAL   (United States)

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CXA 101; CXA 201; FR264205; Pseudomonas aeruginosa

Indexed keywords

BETA LACTAMASE AMPC; BETA LACTAMASE INHIBITOR; CEFEPIME; CEFTAZIDIME; CEFTOLOZANE; CEFTOLOZANE PLUS TAZOBACTAM; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CXA 201; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; MEROPENEM; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM; TAZOBACTAM; UNCLASSIFIED DRUG;

ABDOMINAL INFECTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; BACTERICIDAL ACTIVITY; CONSTIPATION; COUGHING; CROSS RESISTANCE; CYSTIC FIBROSIS; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; ENTEROBACTERIACEAE; FLUSHING; HEADACHE; HEMATURIA; HUMAN; KIDNEY FAILURE; MULTICENTER STUDY (TOPIC); MUSCULOSKELETAL CHEST PAIN; NAUSEA; NONHUMAN; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PSEUDOMONAS AERUGINOSA; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SLEEP DISORDER; SOMNOLENCE; STRUCTURE ACTIVITY RELATION; URINARY TRACT INFECTION; VENTILATOR ASSOCIATED PNEUMONIA; VIRAL UPPER RESPIRATORY TRACT INFECTION;

EID: 84888579845     PISSN: 11786973     EISSN: None     Source Type: Journal    
DOI: 10.2147/IDR.S36140     Document Type: Review

References (55)

1. Carmeli Y, Eliopoulos G, Mozaffari E, Samore M. Health and economic outcomes of vancomycin-resistant enterococci. Arch Intern Med. 2002;162(19):2223-2228.
2. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis. 2003;36(1):53-59.
3. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med. 2006;166(19): 2138-2144.
4. Boucher HW, Talbot GH, Bradley JS, etal. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(1):1-12.
5. Giske CG, Ge J, Nordmann P. Activity of cephalosporin CXA-101 (FR264205) and comparators against extended-spectrum-{beta}-lactamase-producing Pseudomonas aeruginosa. J Antimicrob Chemother. 2009;64(2):430-431.
6. Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis. 2008;197(8):1079-1081.
7. Klevens RM, Edwards JR, Richards CL Jr, etal. Estimating health care-associated infections and deaths in US hospitals, 2002. Public Health Rep. 2007;122(2):160-166.
8. Gaynes R, Edwards JR. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis. 2005;41(6):848-854.
9. Talbot GH, Bradley J, Edwards JE Jr, Gilbert D, Scheld M, Bartlett JG. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis. 2006;42(5):657-668.
10. Centers for Disease Control and Prevention. Gram-negative bacteria infections in healthcare settings. 2011. Available from: http://www.cdc.gov/hai/organisms/gram-negative-bacteria.html. Accessed April 29, 2013.
11. Stein GE. Antimicrobial resistance in the hospital setting: impact, trends, and infection control measures. Pharmacotherapy. 2005;25(10 Pt 2): 44S-54S.
12. Mauldin PD, Salgado CD, Hansen IS, Durup DT, Bosso JA. Attributable hospital cost and length of stay associated with health care-associated infections caused by antibiotic-resistant gram-negative bacteria. Antimicrob Agents Chemother. 2010;54(1):109-115.
13. Agnello M, Wong-Beringer A. Differentiation in quinolone resistance by virulence genotype in Pseudomonas aeruginosa. PloS One. 2012;7(8):e42973.
14. Cosson P, Zulianello L, Join-Lambert O, etal. Pseudomonas aeruginosa virulence analyzed in a Dictyostelium discoideum host system. J Bacteriol. 2002;184(11):3027-3033.
15. Shaver CM, Hauser AR. Relative contributions of Pseudomonas aeruginosa ExoU, ExoS, and ExoT to virulence in the lung. Infect Immun. 2004;72(12):6969-6977.
16. Van Delden C, Iglewski BH. Cell-to-cell signaling and Pseudomonas aeruginosa infections. Emerg Infect Dis. 1998;4(4):551-560.
17. Veesenmeyer JL, Hauser AR, Lisboa T, Rello J. Pseudomonas aeruginosa virulence and therapy: evolving translational strategies. Crit Care Med. 2009;37(5):1777-1786.
18. Giamarellou H, Antoniadou A. Antipseudomonal antibiotics. Med Clin North Am. 2001;85(1):19-42.
19. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004;32(8):470-485.
20. Sievert DM, Ricks P, Edwards JR, etal. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol. 2013;34(1):1-14.
21. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis. March 1, 2002;34(5):634-640.
22. Rossolini GM, Mantengoli E. Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa. Clin Microbiol Infect. 2005;11 Suppl 4:17-32.
23. Kallen AJ, Hidron AI, Patel J, Srinivasan A. Multidrug resistance among gram-negative pathogens that caused healthcare-associated infections reported to the National Healthcare Safety Network, 2006-2008. Infect Control Hosp Epidemiol. 2010;31(5):528-531.
24. Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother. 2006;50(1):43-48.
25. Cao B, Wang H, Sun H, Zhu Y, Chen M. Risk factors and clinical outcomes of nosocomial multi-drug resistant Pseudomonas aeruginosa infections. J Hosp Infect. 2004;57(2):112-118.
26. Livermore DM, Mushtaq S, Ge Y. Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus beta-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother. 2010;65(9):1972-1974.
27. Takeda S, Nakai T, Wakai Y, Ikeda F, Hatano K. In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2007;51(3):826-830.
28. Takeda S, Ishii Y, Hatano K, Tateda K, Yamaguchi K. Stability of FR264205 against AmpC beta-lactamase of Pseudomonas aeruginosa. Int J Antimicrob Agents. 2007;30(5):443-445.
29. Sader HS, Flamm RK, Streit JM, Jones RN. Activity of novel antimicrobial ceftolozane/tazobactam tested against contemporary clinical strains from USA hospitals (2011). In: Abstracts: 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington: American Society for Microbiology; 2012.
30. Toda A, Ohki H, Yamanaka T, etal. Synthesis and SAR of novel parenteral anti-pseudomonal cephalosporins: discovery of FR264205. Bioorg Med Chem Lett. 2008;18(17):4849-4852.
31. Cubist Pharmaceuticals. Ceftolozane/tazobactam-overview. Available from: http://www.cubist.com/sup/img/drugs/Ceft-Taz-overview_880.png. Accessed January 10, 2013.
32. Cubist Pharmaceuticals. Gram-negative: ceftolozane/tazobactam. Available from: http://www.cubist.com/products/cxa_201. Accessed January 10, 2013.
33. Moyá B, Zamorano L, Juan C, Ge Y, Oliver A. Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2010;54(9):3933-3937.
34. Shlaes DM. New β-lactam-β-lactamase inhibitor combinations in clinical development. Ann N Y Acad Sci. 2013;1277:105-114.
35. Mushtaq S, Warner M, Livermore DM, etal. Activity of cephalosporin CXA-101 (FR264205) with β-lactamase inhibitors vs Enterobacteriaceae. In: Abstracts: 48th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington: American Society for Microbiology; 2009.
36. Livermore DM, Mushtaq S, Ge Y, Warner M. Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates. Int J Antimicrob Agents. 2009;34(5):402-406.
37. Moya B, Zamorano L, Juan C, Pérez JL, Ge Y, Oliver A. Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. Antimicrob Agents Chemother. 2010;54(3):1213-1217.
38. Zamorano L, Juan C, Fernández-Olmos A, Ge Y, Cantón R, Oliver A. Activity of the new cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa isolates from chronically-infected cystic fibrosis patients. Clin Microbiol Infect. 2010;16(9):1482-1487.
39. Sader H, Farrell D, Jones RN. Activity of the novel antimicrobial CXA-201 tested against contemporary clinical strains from European hospitals (2012). Presented at: 22nd Annual Meeting of the European Congress of Clinical Microbiology (ECCMID); March 31-April 3, 2012; London, UK.
40. Miller B, Hershberger E, Benziger D, Trinh M, Friedland I. Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses. Antimicrob Agents Chemother. 2012;56(6):3086-3091.
41. Miller B, Chandorkar G, Umeh O, etal. Safety and PK of IV ceftolozane/tazobactam 3g Q8h and cumulative fraction of response in plasma and epithelial lining fluid in a simulated VAP population. In: Abstracts: 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington: American Society for Microbiology; 2012.
42. Ge Y, Whitehouse MJ, Friedland I, Talbot GH. Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single-and multiple-dose intravenous infusions. Antimicrob Agents Chemother. 2010;54(8): 3427-3431.
43. Miller B, Hershberger E, Benziger D, etal. Pharmacokinetics of CXA-101/tazobactam in subjects with mild or moderate renal impairment. Presented at: 21st Annual Meeting of the European Congress of Clinical Microbiology; May 7-10, 2011; Milan, Italy.
44. Chandorkar G, Huntington JA, Gotfried MH, Rodvold KA, Umeh O. Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects. J Antimicrob Chemother. 2012;67(10):2463-2469.
45. Soon RL, Forrest A, Holden PN, etal. In vitro pharmacodynamics of ceftolozane/tazobactam against β-lactamase producing Escherichia coli. In: Abstracts: 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington: American Society for Microbiology; 2012.
46. Craig WA, Andes DR. In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum beta-lactamases, in the thighs of neutropenic mice. Antimicrob Agents Chemother. 2013;57(4):1577-1582.
47. Vanscoy B, Mendes RE, Nicasio AM, etal. Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model. Antimicrob Agents Chemother. 2013;57(6): 2809-2814.
48. Hershberger E, Mouksassi M, Steenbergen JN, etal. CXA-101/tazobactam probability of target attainment using population pharmacokinetic analysis. Presented at: 21st European Congress of Clinical Microbiology and Infectious Diseases and Twenty-seventh International Congress of Chemotherapy; May 7-10, 2011; Milan, Italy.
49. Cabot G, Mulet X, Moya B, etal. Dynamics and mechanisms of resistance development to ceftazidime, meropenem and ceftolozane/tazobactam in wild-type and mutator P. aeruginosa strains. In: Abstracts: 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington: American Society for Microbiology; 2012.
50. ClinicalTrials. gov [website on the Internet]. Safety and efficacy of IV CXA-101 and IV ceftazidime in patients with complicated urinary tract infections. 2010. Available from: http://clinicaltrials.gov/ct2/show/NCT00921024?term=CXA+and+ceftazidime&rank=1. Accessed June 7, 2013.
51. Umeh O, Cebrik D, Friedland I. A double-blind, randomized, phase 2 study to compare the safety and efficacy of intravenous CXA-101 (CXA) and intravenous ceftazidime (CTZ) in complicated urinary tract infection (cUTI). In: Abstracts: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington: American Society for Microbiology; 2010.
52. ClinicalTrials. gov [website on the Internet]. Study of intravenous ceftolozane/tazobactam vs piperacillin/tazobactam in ventilator associated pneumonia. 2013. Available from: http://clinicaltrials.gov/ct2/show/NCT01853982?term=ceftolozane&rank=2. Accessed May 17, 2013.
53. Jacqueline C, Bretonniere C, Desessard C, etal. In vivo activity of CXA-101 against Pseudomonas aeruginosa (PA) in a rabbit experimental model of pneumonia: comparison with ceftazidime (CAZ), piperacillin/tazobactam (TZP), and imipenem (IMP). In: Abstracts: 51st Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington: American Society for Microbiology; 2011.
54. Hsu DI, Okamoto MP, Murthy R, Wong-Beringer A. Fluoroquinolone-resistant Pseudomonas aeruginosa: risk factors for acquisition and impact on outcomes. J Antimicrob Chemother. 2005;55(4):535-541.
55. Nguyen LH, Hsu DI, Ganapathy V, Shriner K, Wong-Beringer A. Reducing empirical use of fluoroquinolones for Pseudomonas aeruginosa infections improves outcome. J Antimicrob Chemother. 2008;61(3):714-720.